Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Total Liabilities (2019 - 2025)

Vivos Therapeutics has reported Total Liabilities over the past 7 years, most recently at $26.7 million for Q4 2025.

  • Quarterly Total Liabilities rose 264.28% to $26.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.7 million through Dec 2025, up 264.28% year-over-year, with the annual reading at $26.7 million for FY2025, 264.28% up from the prior year.
  • Total Liabilities was $26.7 million for Q4 2025 at Vivos Therapeutics, up from $23.1 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $26.7 million in Q4 2025 and troughed at $6.9 million in Q1 2025.
  • The 5-year median for Total Liabilities is $9.5 million (2022), against an average of $11.3 million.
  • Year-over-year, Total Liabilities soared 403.67% in 2021 and then plummeted 38.51% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $8.2 million in 2021, then rose by 9.44% to $8.9 million in 2022, then rose by 15.7% to $10.3 million in 2023, then dropped by 28.97% to $7.3 million in 2024, then surged by 264.28% to $26.7 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Total Liabilities are $26.7 million (Q4 2025), $23.1 million (Q3 2025), and $21.5 million (Q2 2025).